Pseudoephedrine

  • TRADE NAMES: Allegra-D (Sanofi-Aventis); Balminil; Benadryl (Pfizer); Bromfed (Muro); Deconsal; Eltor 120; Entex (Andrx); Maxiphed; Robidrine; Robitussin-CF (Wyeth); Sudafed (Pfizer); Trinalin (Schering)
  • INDICATIONS: Nasal congestion
  • CLASS: Adrenergic alpha-receptor agonist
  • HALF-LIFE: 9–16 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Bromocriptine, Fluoxetine, Fluvoxamine, Furazolidone, Iobenguane, MAO inhibitors, Paroxetine Hydrochloride, Phenelzine, Rasagiline, Sertraline, Tranylcypromine

PREGNANCY CATEGORY: C

NOTE

(February 2023) The European Medicines Agency has started a review of medicines containing pseudoephedrine following concerns about the risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) from the use of over-the-counter decongestants containing pseudoephedrine.

Our database has 40 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 08/02/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top